Halofuginone, an inhibitor of type-I collagen synthesis and skin sclerosis, blocks transforming-growth-factor-β-mediated Smad3 activation in fibroblasts

Tracy L. McGaha, Robert G. Phelps, Harry Spiera, Constantin Bona

Research output: Contribution to journalArticle

144 Citations (Scopus)

Abstract

Halofuginone is a drug that has been shown to have an antifibrotic property in vitro and in vivo. Whereas halofuginone shows promise as a therapeutic agent for a variety of diseases including scleroderma, liver cirrhosis, cystic fibrosis, and certain types of cancer, the mechanism of action remains unknown. Using the tight skin mouse (TSK) model for scleroderma, we evaluated the ability of halofuginone to inhibit spontaneous development of dermal fibrosis. We found that administration of a low dose of halofuginone both in adult and newborn animals for 60 d prevented the development of cutaneous hyperplasia (dermal fibrosis). In vitro halofuginone was found to reduce the amount of collagen synthesized by fibroblasts. This effect was due to a reduction in the promoter activity of the type-I collagen genes as treatment of fibroblast cultures with 10-8 M halofuginone reduced the level of α2(I) collagen message detectible by northern blot and greatly reduced the activity of a reporter construct under control of the -3200 to +54 bp α2(I) collagen promoter. In addition, analysis of transforming growth factor β signaling pathways in fibroblasts revealed that halofuginone inhibited transforming-growth-factor-β-induced upregulation of collagen protein and activity of the α2(I) collagen promoter. Further we found that halofuginone blocked the phosphorylation and subsequent activation of Smad3 after transforming growth factor β stimulation. Apparently the inhibitory property was specific to Smad3 as there was no inhibitory effect on the activation of Smad2 after stimulation with transforming growth factor β. Our results demonstrate that halofuginone is a specific inhibitor of type-I collagen synthesis and may elicit its effect via interference with the transforming growth factor β signaling pathway.

Original languageEnglish (US)
Article number5601419
Pages (from-to)461-470
Number of pages10
JournalJournal of Investigative Dermatology
Volume118
Issue number3
DOIs
StatePublished - Jan 1 2002

Fingerprint

Transforming Growth Factors
Sclerosis
Fibroblasts
Collagen Type I
Skin
Chemical activation
Collagen
Fibrosis
Newborn Animals
halofuginone
Phosphorylation
Cell culture
Cystic Fibrosis
Liver Cirrhosis
Northern Blotting
Liver
Hyperplasia
Animals
Up-Regulation
Genes

Keywords

  • Fibrosis
  • Scleroderma
  • Signal transduction
  • TGF-β
  • Tight skin

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Dermatology
  • Cell Biology

Cite this

Halofuginone, an inhibitor of type-I collagen synthesis and skin sclerosis, blocks transforming-growth-factor-β-mediated Smad3 activation in fibroblasts. / McGaha, Tracy L.; Phelps, Robert G.; Spiera, Harry; Bona, Constantin.

In: Journal of Investigative Dermatology, Vol. 118, No. 3, 5601419, 01.01.2002, p. 461-470.

Research output: Contribution to journalArticle

@article{d84ff802ded543eca1ba79e98e9e118c,
title = "Halofuginone, an inhibitor of type-I collagen synthesis and skin sclerosis, blocks transforming-growth-factor-β-mediated Smad3 activation in fibroblasts",
abstract = "Halofuginone is a drug that has been shown to have an antifibrotic property in vitro and in vivo. Whereas halofuginone shows promise as a therapeutic agent for a variety of diseases including scleroderma, liver cirrhosis, cystic fibrosis, and certain types of cancer, the mechanism of action remains unknown. Using the tight skin mouse (TSK) model for scleroderma, we evaluated the ability of halofuginone to inhibit spontaneous development of dermal fibrosis. We found that administration of a low dose of halofuginone both in adult and newborn animals for 60 d prevented the development of cutaneous hyperplasia (dermal fibrosis). In vitro halofuginone was found to reduce the amount of collagen synthesized by fibroblasts. This effect was due to a reduction in the promoter activity of the type-I collagen genes as treatment of fibroblast cultures with 10-8 M halofuginone reduced the level of α2(I) collagen message detectible by northern blot and greatly reduced the activity of a reporter construct under control of the -3200 to +54 bp α2(I) collagen promoter. In addition, analysis of transforming growth factor β signaling pathways in fibroblasts revealed that halofuginone inhibited transforming-growth-factor-β-induced upregulation of collagen protein and activity of the α2(I) collagen promoter. Further we found that halofuginone blocked the phosphorylation and subsequent activation of Smad3 after transforming growth factor β stimulation. Apparently the inhibitory property was specific to Smad3 as there was no inhibitory effect on the activation of Smad2 after stimulation with transforming growth factor β. Our results demonstrate that halofuginone is a specific inhibitor of type-I collagen synthesis and may elicit its effect via interference with the transforming growth factor β signaling pathway.",
keywords = "Fibrosis, Scleroderma, Signal transduction, TGF-β, Tight skin",
author = "McGaha, {Tracy L.} and Phelps, {Robert G.} and Harry Spiera and Constantin Bona",
year = "2002",
month = "1",
day = "1",
doi = "10.1046/j.0022-202x.2001.01690.x",
language = "English (US)",
volume = "118",
pages = "461--470",
journal = "Journal of Investigative Dermatology",
issn = "0022-202X",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Halofuginone, an inhibitor of type-I collagen synthesis and skin sclerosis, blocks transforming-growth-factor-β-mediated Smad3 activation in fibroblasts

AU - McGaha, Tracy L.

AU - Phelps, Robert G.

AU - Spiera, Harry

AU - Bona, Constantin

PY - 2002/1/1

Y1 - 2002/1/1

N2 - Halofuginone is a drug that has been shown to have an antifibrotic property in vitro and in vivo. Whereas halofuginone shows promise as a therapeutic agent for a variety of diseases including scleroderma, liver cirrhosis, cystic fibrosis, and certain types of cancer, the mechanism of action remains unknown. Using the tight skin mouse (TSK) model for scleroderma, we evaluated the ability of halofuginone to inhibit spontaneous development of dermal fibrosis. We found that administration of a low dose of halofuginone both in adult and newborn animals for 60 d prevented the development of cutaneous hyperplasia (dermal fibrosis). In vitro halofuginone was found to reduce the amount of collagen synthesized by fibroblasts. This effect was due to a reduction in the promoter activity of the type-I collagen genes as treatment of fibroblast cultures with 10-8 M halofuginone reduced the level of α2(I) collagen message detectible by northern blot and greatly reduced the activity of a reporter construct under control of the -3200 to +54 bp α2(I) collagen promoter. In addition, analysis of transforming growth factor β signaling pathways in fibroblasts revealed that halofuginone inhibited transforming-growth-factor-β-induced upregulation of collagen protein and activity of the α2(I) collagen promoter. Further we found that halofuginone blocked the phosphorylation and subsequent activation of Smad3 after transforming growth factor β stimulation. Apparently the inhibitory property was specific to Smad3 as there was no inhibitory effect on the activation of Smad2 after stimulation with transforming growth factor β. Our results demonstrate that halofuginone is a specific inhibitor of type-I collagen synthesis and may elicit its effect via interference with the transforming growth factor β signaling pathway.

AB - Halofuginone is a drug that has been shown to have an antifibrotic property in vitro and in vivo. Whereas halofuginone shows promise as a therapeutic agent for a variety of diseases including scleroderma, liver cirrhosis, cystic fibrosis, and certain types of cancer, the mechanism of action remains unknown. Using the tight skin mouse (TSK) model for scleroderma, we evaluated the ability of halofuginone to inhibit spontaneous development of dermal fibrosis. We found that administration of a low dose of halofuginone both in adult and newborn animals for 60 d prevented the development of cutaneous hyperplasia (dermal fibrosis). In vitro halofuginone was found to reduce the amount of collagen synthesized by fibroblasts. This effect was due to a reduction in the promoter activity of the type-I collagen genes as treatment of fibroblast cultures with 10-8 M halofuginone reduced the level of α2(I) collagen message detectible by northern blot and greatly reduced the activity of a reporter construct under control of the -3200 to +54 bp α2(I) collagen promoter. In addition, analysis of transforming growth factor β signaling pathways in fibroblasts revealed that halofuginone inhibited transforming-growth-factor-β-induced upregulation of collagen protein and activity of the α2(I) collagen promoter. Further we found that halofuginone blocked the phosphorylation and subsequent activation of Smad3 after transforming growth factor β stimulation. Apparently the inhibitory property was specific to Smad3 as there was no inhibitory effect on the activation of Smad2 after stimulation with transforming growth factor β. Our results demonstrate that halofuginone is a specific inhibitor of type-I collagen synthesis and may elicit its effect via interference with the transforming growth factor β signaling pathway.

KW - Fibrosis

KW - Scleroderma

KW - Signal transduction

KW - TGF-β

KW - Tight skin

UR - http://www.scopus.com/inward/record.url?scp=0036121027&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036121027&partnerID=8YFLogxK

U2 - 10.1046/j.0022-202x.2001.01690.x

DO - 10.1046/j.0022-202x.2001.01690.x

M3 - Article

C2 - 11874485

AN - SCOPUS:0036121027

VL - 118

SP - 461

EP - 470

JO - Journal of Investigative Dermatology

JF - Journal of Investigative Dermatology

SN - 0022-202X

IS - 3

M1 - 5601419

ER -